

Table S1. Imaging mass cytometry panel

Short name (gene)	Clone	source	Isotope	Dilution	Conditions
alpha-SMA	IA4	STBT	141Nd	1/400	4°
Collagen Type I	ABT123	Merck	143Nd	1/100	4°
CD14	EPR3653	STBT	144Nd	1/100	4°
pankeratin	C11	STBT	148Nd	1/100	4°
CD15	W6D3	STBT	149Sm	1/50	4°
CD107A	H4A3	STBT	151Eu	1/50	4°
CD45(PTPRC)	D9M81	STBT	152Sm	1/200	4°
CD11c (ITGAX)	EP134Y	Abcam	154Sm	1/200	4°
CD4	EPR6855	STBT	156Gd	1/100	4°
E-Cadherin	24-E10	STBT	158Gd	1/200	4°
CD68	KP1	STBT	159Tb	1/800	4°
CD20 (MS4A1)	H1	STBT	161Dy	1/400	4°
CD8a	C8/144B	STBT	162Dy	1/200	4°
VEGF	G 153-694	STBT	163Dy	1/100	4°
Granzyme B	EPR20129-21	STBT	167Er	1/200	4°
CD45RA(PTPRC)	HI100	STBT	169Er	1/200	4°
CD3	Polyclonal	STBT	170Er	1/100	4°
CD16 (FCGR3A)	EPR16784	Abcam	172Yb	1/200	4°
HLADR	LN3	STBT	174Yb	1/1600	4°
CD56	E7X9M rabbit	Ozyme	155Gd	1/100	4°
HLAG	MEM-G/2	Invitrgen	145Nd	1/100	4°
DC SIGN	NBP1-77284	BioTechne	166Er	1/100	4°
CD69	EPR21814	Abcam	165Ho	1/50	4°
Integrin β 7	FIB504	Invitrogen	176Yb	1/100	4°
ACE2	A200691	Biologend	175Yb	janv-50	4°
Iridium	201192A	STBT	191Ir	1/400	4°
CD27	EPR8569	STBT	171Yb	1/50	1h30 RT

Table S2: Imaging mass cytometry density of the cells (number/mm²) according the biopsies

	Cervical biopsy Control	Cervical biopsy UTx 30 months	Cervical biopsy UTx explantation	Uterine fundus Biopsy UTx explantation
Bcells	0	5	106	2
Endothelials	1243	1904	928	660
Epithelials	1856	929	563	131
LT4	211	184	299	49
LT8	284	128	429	77
Macro	75	161	667	18
Mono	10	31	313	2
undefined	381	321	708	55
Total cells	3662	2111	3778	1292

Table S3. List of flow cytometry markers in blood samples

Marker	Clone	Fluorochrom	Company
NK Cells			
CD3	UCHT1	eFluor780	eBioscience
CD16	REA423	PerCP-Vio 700	Miltenyi Biotec
CD56	REA196	PEVio770	Miltenyi Biotec
CD161	DX12	FITC	BD Pharmingen
CD69	TP1.55.3	ECD	Coulter
HLA-DR	I243	AlexaFluor 700	BioLegend
CD57	NC1	Pacific Blue	Coulter
NKG2A	Z199	Phycoerythrin	Coulter
NKG2C	#134591	Allophycocyanin	R&D System
NKG2D	1D11	Brilliant Violet 786	BD Optibuild
NKp30	P30-15	Brilliant Violet 421	BD Pharmingen
NKp46	REA808	PEVio615	Miltenyi Biotec
KIR2DL1	HP-3E4	FITC	BD Pharmingen
KIR2DL2/DL3	GL183	Phycoerythrin	Coulter
KIR3DL1	DX9	AlexaFluor-700	Biolegend
ILT2	GHI/75	Allophycocyanin	Miltenyi Biotec
DNAM-1	DX11	Brilliant Violet 650	BD Optibuild
CD107a	H4A3	FITC	BD Pharmingen
IFN- γ	B27	AlexaFluor-700	BD Pharmingen
TNF- α	Mab11	eFluor450	eBioscience
Viability		eFluor506	eBioscience
T Cells			
CD45-RA	5H9	FITC	BD Pharmingen
CD38	HB7	PE	BD Pharmingen
CD8	B9.11	ECD	Beckman
CD27	L128	PerCP-Cy 5.5	BD Pharmingen
CCR7 (CD197)	3D12	PE-Cy 7	BD Pharmingen
CD45-RA	RPA-T4	APC	BD Pharmingen
HLA-DR	I243	AF700	BioLegend
CD3	UCHT1	eFluor780	eBioscience
CD57	NC1	Pacific Blue	Beckman
Viability		eF506	eBioscience
B Cells			
IgD	IA6-2	FITC	BD Pharmingen
CD11c	3.9	PE	BD Pharmingen
CD3	UCHT1	PE-CF594	BD Pharmingen
CD14	MoP9	PE-CF594	BD Pharmingen
CD38	HIT2	PerCP-Cy 5.5	BD Pharmingen
CD27	M-T271	PE-Cy 7	BD Pharmingen
CD21	B-ly4	APC	BD Pharmingen
CD19	HIB19	AR700	BD Pharmingen
IgM	G20-127	BV510	BD Pharmingen
CD24	ML5	BV650	BD Pharmingen
Viability		eF780	eBioscience

Suppl. Fig. 1: Micrographs showing negative c4d staining in two representative cervical biopsy taken from the UTx recipient. A: 14 days after UTx; B: 8 months after UTx (showing borderline lesions)

